NCT06937268

DOTATATE PET for Meningioma Radiation Planning

Exploratory Analysis of DOTATATE PET for Meningioma Radiation Planning

• Status: Not Yet Recruiting
• Phase: N/A
• Study type: Interventional
• Enrollment: 36 (estimated)
• Sponsor: British Columbia Cancer Agency · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

68Ga-DOTATATE-based radionuclides are a novel modality in the diagnosis and treatment of central nervous system meningioma. DOTATATE is a ligand for the SSTR (somatostatin receptor), which is expressed in meningioma but not in normal brain or bone. It is also more effective than MRI in delineating tumor, which is the current imaging standard for assessing meningioma. For radiation planning, it can help to reduce the risk of geometrical miss, identify area that require dose-escalation, and reduce dose to normal tissue. The purpose of the study is to compare the radiation therapy (RT) contouring and planning for meningioma with and without the use of 68Ga-DOTATATE-PET

Conditions

• Meningioma

Interventions

Type	Name	Description
DIAGNOSTIC_TEST	DOTATATE-PET scan	DOTATATE tracer PET scan for meningioma

Timeline

• Start date: 2025-06-01
• Primary completion: 2026-12-31
• Completion: 2027-12-31
• First posted: 2025-04-22
• Last updated: 2025-04-22

Locations

1 site across 1 country: Canada